Drugs /

autologous cmv-pp65-fllamp mrna loaded dendritic cell vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the autologous CMV-pp65-flLAMP mRNA loaded DC vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.

Clinical Trials

View Clinical Trials for autologous cmv-pp65-fllamp mrna loaded dendritic cell vaccine

Autologous cmv-pp65-fllamp mrna loaded dendritic cell vaccine has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating autologous cmv-pp65-fllamp mrna loaded dendritic cell vaccine, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).

MGMT Promoter Methylation Negative is the most frequent biomarker inclusion criterion for autologous cmv-pp65-fllamp mrna loaded dendritic cell vaccine clinical trials.

Glioblastoma is the most common disease being investigated in autologous cmv-pp65-fllamp mrna loaded dendritic cell vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Autologous Cmv-Pp65-Fllamp Mrna Loaded Dendritic Cell Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating autologous cmv-pp65-fllamp mrna loaded dendritic cell vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
autologous pp65-fllamp dcs, autologous pp65-fllamp dc vaccine, autologous cmv-pp65-fllamp dcs, autologous fllamp-pp65 mrna-pulsed dc vaccine, autologous fllamp-pp65-dc vaccine, autologous fllamp-pp65-dcs, autologous cmv pp65-lamp mrna-loaded dc vaccine
NCIT ID [1]:
C156067

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.